Evaluation of a New Potential Bevacizumab Biosimilar in Corneal Neovascularization
This experimental study showed that the potential bevacizumab biosimilar anti-human VEGF GU01 was as effective as subconjunctival bevacizumab in the treatment of CNV.
Authors
- Armağan Özgür (ORCID: https://orcid.org/0000-0001-9111-8060)
- Mehmet Arda İnan (ORCID: https://orcid.org/0000-0002-6179-2828)
- Emin Ümit Bağrıaçık (ORCID: https://orcid.org/0000-0002-8066-5816)
- Mehmet Cüneyt Özmen
- Nilüfer Yeşilırmak
Institutions
- Memorial Ankara Hospital (TR)
- Başkent University Hospital (TR)
- Ankara Yıldırım Beyazıt University (TR)
- Gazi University (TR)
Publication Details
- Journal
- Turkish Journal of Ophthalmology
- Published
- 2025-12-25
- DOI
- https://doi.org/10.4274/tjo.galenos.2025.34783
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00